It’s no surprise that healthcare startups are synonymous with future of the industry. The smaller and more agile companies are increasingly offering solutions to a number of healthcare problems arising around the country.
Indeed, the growth of this industry is reflected in the increase in investment by VCs. According to a recent analysis by Pitchbook, healthcare startups have raised over $15 billion from venture capitalists, over 70% more than in the same period last year.
As a healthcare executive, keeping track of developments in the startup world is essential in order to stay on top of technological trends in the industry.
We’ve found the 10 most-funded healthcare startups in the U.S.:
Grail is a life sciences company that aims to detect cancer at an earlier stage, when it can possibly be cured. The company leverages data and computer science to improve scientific understanding of cancer biology and develop blood tests for early-stage cancer detection.
Total funding: $1.6B
Last Funding Round: $300M, Series C, May 2018
Based in San Francisco, Clover Health uses data analysis and preventive care to help seniors and private holders of Medicare find more affordable insurance options. The company’s technology recognizes when patients need treatment and intervenes with its own team of nurse practitioners and social workers to provide savings for both the member and the insurance company.
Total funding: $425M
Last Funding Round: $130M, Series D, May 2017
Gossamer Bio is a biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflammation, immuno-oncology, and fibrosis disease areas. Gossamer Bio places large importance on fostering and maintaining relationships within the healthcare system. Check out our coverage of their recent funding round here.
Total funding: $330M
Last Funding Round: $230M, Series B, July 2018
Founded in 2015, Helix is focused on empowering lives through DNA. Helix is creating an ecosystem through which people can explore diverse and uniquely personalized platforms provided by partners. Using the DNA sample collection, sequencing, and data storage provided by Helix, these partners develop on-demand products in health, fitness, nutrition, lifestyle, inherited traits, and genealogy.
Total funding: $320M
Last Funding Round: $200M, Series B, March 2018
Human Longevity’s goal is to build the world’s largest library of genotypes and phenotypes, and to use machine learning in order to fight diseases associated with aging. The company offers a service they call ‘Health Nucleus,’ through which they offer customers a variety of medical tests including phenotype sequencing, and tests for early indications of cancers, Alzheimer’s, and heart disease.
Total funding: $300M
Last Funding Round: $220M, Series B, April 2016
Collective Health is powering the employer-driven healthcare economy with their health management system, the Collective Health Platform. The platform combines health plans, concierge support, an engagement hub, and analytics, giving employers a comprehensive tool to best manage their healthcare investment.
Total funding: $267M
Last Funding Round: $110M, Series D, February 2018
Livongo is committed to driving behaviour change among those with chronic conditions through the use of consumer health technology, personalized recommendations, and real-time support. They make it easier for people to stay healthy, and their services include diabetes prevention and hypertension offerings.
Total funding: $240M
Last Funding Round: $105M, Series E, April 2018
BlueRock Therapeutics is developing cell-based medicine that repairs the body when it cannot repair itself, and is committed to those with degenerative disease. BlueRock’s approach can be applied to diversified therapeutic programs, and the company is currently targeting brain and heart conditions.
Total funding: $225M
Last Funding Round: $225M, Series A, Dec 2016
AJAX Health is a clinical-stage platform company focussed on developing medical technologies. AJAX invests and takes an operating role in medical companies that they believe make healthcare more efficient and simple. The firm is led by Duke Rohlen, a medical device veteran of over fifteen years.
Total funding: $215M
Last Funding Round: $120M, Series B, July 2018
Tempus aims to usher in a new era of Precision Medicine. They’ve built the world’s largest library of clinical and molecular data, and have dovetailed it with an operating system to make it accessible to patients, physicians, and researchers. This allows physicians to deliver personalized cancer care, and make real-time, data-driven decisions.
Total funding: $210M
Last Funding Round: $80M, Series D, March 2018
Funding information in this article is sourced from Crunchbase, years of establishment are from company LinkedIn profiles, and CEO information and logos are from company websites.